These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9250591)

  • 1. A novel antifolate, MX-68, inhibits the development of autoimmune disease in MRL/lpr mice.
    Mihara M; Takagi N; Urakawa K; Moriya Y; Takeda Y
    Int Arch Allergy Immunol; 1997 Aug; 113(4):454-9. PubMed ID: 9250591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventive effect of a novel antifolate, MX-68, in murine systemic lupus erythematosus (SLE).
    Mihara M; Takagi N; Urakawa K; Moriya Y; Takeda Y
    Int J Immunopharmacol; 1997 Feb; 19(2):67-74. PubMed ID: 9278176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel non-polyglutamable anti-folate, MX-68, inhibits the induction of experimental autoimmune uveitis in rats.
    Hiraoka M; Mihara M; Takeda Y; Miyasaka N
    Exp Eye Res; 1998 Jul; 67(1):1-8. PubMed ID: 9702173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of methotrexate treatment on the onset of autoimmune kidney disease in lupus mice.
    Mihara M; Katsume A; Takeda Y
    Chem Pharm Bull (Tokyo); 1992 Aug; 40(8):2177-81. PubMed ID: 1423777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyglutamation of a novel antifolate, MX-68, is not necessary for its anti-arthritic effect.
    Urakawa K; Mihara M; Takagi N; Kawamura A; Akamatsu K; Takeda Y
    Eur J Pharmacol; 2002 Jan; 435(2-3):237-44. PubMed ID: 11821032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice.
    Atkinson C; Qiao F; Song H; Gilkeson GS; Tomlinson S
    J Immunol; 2008 Jan; 180(2):1231-8. PubMed ID: 18178863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive properties of MX-68, a novel unpolyglutamatable antifolate.
    Mihara M; Suzuki T; Kaneko E; Takagi N; Takeda Y
    Biol Pharm Bull; 1997 Oct; 20(10):1071-5. PubMed ID: 9353567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of several kinds of drugs on the development of autoimmunity in MRL/Mp-lpr/lpr mice; lack of correlation between the suppression of autoantibody production and prevention of autoimmune disease.
    Mihara M; Ohsugi Y
    J Pharmacobiodyn; 1989 Feb; 12(2):100-6. PubMed ID: 2526211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of MX-68 on airway inflammation and hyperresponsiveness in mice and guinea-pigs.
    Nagao K; Akabane H; Masuda T; Komai M; Tanaka H; Nagai H
    J Pharm Pharmacol; 2004 Feb; 56(2):187-96. PubMed ID: 15005877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An immunomodulating anti-rheumatic drug, lobenzarit disodium (CCA): inhibition of polyclonal B-cell activation and prevention of autoimmune disease in MRL/Mp-lpr/lpr mice.
    Mihara M; Nakano T; Ohsugi Y
    Clin Immunol Immunopathol; 1987 Dec; 45(3):366-74. PubMed ID: 3500002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice.
    Sadanaga A; Nakashima H; Masutani K; Miyake K; Shimizu S; Igawa T; Sugiyama N; Niiro H; Hirakata H; Harada M
    Arthritis Rheum; 2005 Dec; 52(12):3987-96. PubMed ID: 16320345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term administration of cyclophosphamide in MRL/1 mice. I. The effects on the development of immunological abnormalities and lupus nephritis.
    Shiraki M; Fujiwara M; Tomura S
    Clin Exp Immunol; 1984 Feb; 55(2):333-9. PubMed ID: 6607792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effects of autoimmune disease by green tea in MRL-Faslprcg/Faslprcg mice.
    Sayama K; Oguni I; Tsubura A; Tanaka S; Matsuzawa A
    In Vivo; 2003; 17(6):545-52. PubMed ID: 14758719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CS-A therapy in MRL-lpr/lpr mice: amelioration of immunopathology despite autoantibody production.
    Mountz JD; Smith HR; Wilder RL; Reeves JP; Steinberg AD
    J Immunol; 1987 Jan; 138(1):157-63. PubMed ID: 3537128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo biological activities of a novel nonpolyglutamable anti-folate, MX-68.
    Mihara M; Urakawa K; Takagi N; Moriya Y; Takeda Y
    Immunopharmacology; 1996 Oct; 35(1):41-6. PubMed ID: 8913793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment of the MRL/lpr mouse with methotrexate and 10-deazaaminopterin.
    Baggott JE; Morgan SL; Freeberg LE; Hudson BB; Vaughn WH; Gopal Nair M; Krumdieck CL; Koopman WJ; Gay RE; Gay S
    Agents Actions; 1992 Jan; 35(1-2):104-11. PubMed ID: 1509970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ-lpr/lpr mice.
    Entani C; Izumino K; Iida H; Fujita M; Asaka M; Takata M; Sasayama S
    Nephron; 1993; 64(3):471-5. PubMed ID: 7688103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of lupus nephritis in MRL/lpr mice by a bacterial superantigen treatment.
    Kim C; Siminovitch KA; Ochi A
    J Exp Med; 1991 Dec; 174(6):1431-7. PubMed ID: 1744580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the role of the lpr gene in the development of immunological abnormalities and lupus nephritis. Analyses in F2 mice.
    Fujiwara M; Kariyone A; Shiraki M
    Clin Exp Immunol; 1985 Jan; 59(1):161-8. PubMed ID: 3918816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic targeting of BET protein BRD4 delays murine lupus.
    Wei S; Sun Y; Sha H
    Int Immunopharmacol; 2015 Dec; 29(2):314-319. PubMed ID: 26590112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.